echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > 7 auxiliary examination methods to diagnose early-onset Parkinson's!

    7 auxiliary examination methods to diagnose early-onset Parkinson's!

    • Last Update: 2023-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    For medical professionals only

    For more guidelines for the diagnosis and treatment of common neurological diseases, go to the "Clinical Decision Assistant App"!


     


    Parkinson's disease (PD) is a common neurodegenerative disease that increases in prevalence with age [1].


    Although PD is currently more common in the elderly, recent studies have found that some patients have an onset age earlier than 50 years old, called early-onset PD (early-onset Parkinson's disease, EOPD), accounting for 5%~10% of PD [2-4].


    To determine whether it is early-onset Parkinson's disease, the "Chinese Expert Consensus on the Diagnosis and Treatment of Early-onset Parkinson's Disease" points out the following 7 auxiliary examination methods, let's take a look! Early detection, early intervention!



    1.
    Serological examination


    • Serum copper, serum ceruloplasmin, etc.
      are helpful in differentiating
      Wilson disease (HLD).



    2.
    Electrophysiological examination


    • EMG tremor testing is helpful in the analysis and evaluation
      of tremor frequency, amplitude, and type.



    Third, olfactory evaluation
    • Sniffin's Sticks test assesses olfactory function
      .



    4.
    Neuroimaging examination

    1.
    Structural brain CT and MRI routine sequence examination


    • EOPD has no characteristic changes
      .


    • It can distinguish HLD, spinal cerebellar ataxia (SCA), Huntington's disease (HD), and neurodegenerative disease of iron deposition in brain tissue (NBIA).


    2, positron emission computed tomography (PET/PET-CT), single-photon emission computed tomography (SPECT)


    • Dopamine transporter (DAT) tracer imaging showing decreased uptake in the basal ganglia suggests EOPD
      .


    3.
    Ultrasonic testing


    • EOPD shows abnormal enhancement of substantia nigra echo (>20mm2), large substantia nigra echo volume, and significantly enhanced substantia nigra
      echo.



    Fifth, intercardiac iodobenzylguanidine scintigraphy
    • May show cardiac desympathetic innervation, but EOPD may not be as suggestive as iPD
      .



    6.
    Clinical scoring scale

    • Useful in understanding the clinical symptoms and severity
      of EOPD patients.


    • The International Society of Movement Disorders Parkinson's Disease Composite Rating Scale (MDS-UPDRS) and Hoehn-Yahr Staging Scale assess motor symptoms, motor complications, and disease severity
      .


    • The Non-Motor Symptom Rating Scale (NMSS), the Mini-Mental State Assessment Scale (MMSE), the Montreal Cognitive Scale (MoCA), and the Hamilton Depression Scale (HAMD) assess non-motor symptoms
      .


    • A specific type of rating scale may be used to assess a particular aspect in detail
      .



    7.
    Genetic testing

    • It can identify the cause and assist in diagnosis and differential diagnosis
      .


    • Genetic counseling is required before testing, including family history, age of onset, clinical phenotype, etc
      .


    • Detection technology methods and strategies: Sanger sequencing, next-generation sequencing
      .


    • For Parkin, SNCA and other genes, multiple ligation probe amplification (MLPA) must be used to complete gene copy number detection
      .


    • Denatured polyacrylamide electrophoresis and capillary electrophoresis were used to detect polynucleotide repeat amplification mutations, which could exclude SCA and HD
      .


    • Parkin, GBA, LRRK2, PLA2G6, PINK1, SNCA, VPS13C, ATP13A2, VPS35, DJ-1 and other tests were carried
      out.


    What are the recommended medications for early-onset Parkinson's disease?

    What are the precautions for using anti-Parkinson's drugs?


    Open the Decision Assistant App Clinical Guidelines module

    Search for disease names, dialogue with authoritative guides at home and abroad! 👇

    Download the Decision Assistant App, the guide is free at any time~

    References: [1] Poewe W, Seppi K, Tanner CM, et al.
    Parkinson disease[J].
    Nat Rev Dis Primers,2017,3:17013.
    DOI:10.
    1038/nrdp.
    2017.
    13.
    [2]Schrag A,Schott JM.
    Epidemiological,clinical,and genetic characteristics of early-onset parkinsonism[J].
    Lancet Neurol,
    2006,5(4):355-363.
    DOI:10.
    1016/S1474-4422(06)70411-2.
    [3]Niemann N,Jankovic J.
    Juvenile parkinsonism:differential
    diagnosis,genetics,and treatment[J].
    Parkinsonism Relat Disord,
    2019,67:74-89.
    DOI:10.
    1016/j.
    parkreldis.
    2019.
    06.
    025.
    [4]Mehanna R,Jankovic J.
    Young-onset Parkinson's disease:its
    unique features and their impact on quality of life[J].
    Parkinsonism RelatDisord,2019,65:39-48.
    DOI:10.
    1016/j.
    parkreldis.
    2019.
    06.
    001.
    [5] Chinese expert consensus on the diagnosis and treatment of early-onset Parkinson's disease ▼▼Click to read the original article to download the App

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.